Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Research suggests screening for latent coronary artery disease to decrease complications.
Read More »Dyslipidemia Pattern And Ischemic Heart Disease In Type 2 Diabetes Patients
Obesity and Life Expectancy in Older Diabetes Patients
The treatment of choice for obese T2D patients is weight loss.
Read More »Beta Blockers And the Risk of CV Events in Type 2 Diabetes
Beta-blocker use in patients with T2DM and established CV risk factors associated with increased risk of CV events and severe hypoglycemia, according to recent study.
Read More »Lipid-Lowering Effect of Extra Virgin Olive Oil and Atorvastatin in Type 2 Diabetes
Extra virgin olive oil, like statins, promotes lipid lowering in people with diabetes who have dyslipidemia.
Read More »Estimating Concentrations of Chromium and Manganese in Diabetes Patients
Serum concentration levels of both chromium and manganese metals are altered in people with and without diabetes.
Read More »Link Between Serum Bilirubin and Diabetic Retinopathy in Type 2 Diabetes Patients
Serum bilirubin is inversely correlated with diabetic retinopathy predicting progression of retinopathy over time.
Read More »Ramadan Fasting and Type 2 Diabetes
Fasting found to lead to deterioration of glycemic control in people with type 2 diabetes.
Read More »Use of SGLT-2 inhibitors As Adjunct to Insulin In People with Type 1 Diabetes
Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.
Read More »Glucose Self-Monitoring For Non-Insulin Using Patients Did Not Improve Control
The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated over the years.
Read More »Liraglutide Gets FDA Indication For Reducing CVD Risk, But Not So Fast
The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.
Read More »